



**Europäisches
Patentamt**

**European
Patent Office**

**Office européen
des brevets**

Bescheinigung

Certificate

Attestation

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

01108414.2

Der Präsident des Europäischen Patentamts:
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

R C van Dijk



Anmeldung Nr:
Application no.: 01108414.2
Demande no:

Anmeldetag:
Date of filing: 03.04.01
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

SOCIETE DES PRODUITS NESTLE S.A.
Case postale 353
1800 Vevey
SUISSE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se référer à la description.)

Osteoprotegerin in Milk

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)
revendiquée(s)

Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

/00.00.00/

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

A23C/

Am Anmeldetag benannte Vertragsstaaten/Contracting states designated at date of
filing/Etats contractants désignées lors du dépôt:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

SECRET

100-100000

100-100000

100-100000

100-100000

100-100000

100-100000

100-100000

100-100000

100-100000

100-100000

100-100000

Applicant:
Our file:

Société Des Produits Nestlé S.A.
80280/EP

EPO - Munich
74
03 April 2001

Osteoprotegerin In Milk

The present invention pertains to osteoprotegerin obtainable from milk sources, in particular human and bovine milk. The present invention also relates to the use thereof for preparing an ingestible preparation and/or a pharmaceutical composition, in particular to the use of such a preparation/composition for preventing or treating disorders associated with bone metabolism and immune function.

In mammals, the bones provide support for the body and consist of minerals, a matrix of collagenous and non-collagenous proteins, and a cellular component. The growth and maintenance thereof is controlled by a variety of different factors involving regulation and interaction of its component cell types, i.e. the chondrocytes which form cartilage, the osteoblasts which synthesize and deposit bone matrix, and the osteoclasts responsible for resorption of bone material.

Chondrocytes are derived from mesenchymal cells and generate an initial cartilage template required for endochondral bone formation. Osteoblasts, which promote formation of bone tissue, are derived from mesenchymal osteoprogenitor cells and are located on the surface of bones where they synthesize, transport and arrange the matrix proteins. On the other hand, osteoclasts, which are responsible for bone resorption, are derived from granulocyte-monocyte precursors present in the hematopoietic marrow. The actions of osteoclasts and osteoblasts are tightly linked e.g. during the process of osteoclast mediated resorption, the protein factors which are elaborated act as signaling molecules to initiate bone renewal by osteoblasts. Osteoblasts, in turn, may influence osteoclast function through expression of soluble or membrane bound regulators. Normal bone remodeling is therefore dependent on a definite balance between the opposing functions of bone formation and bone resorption as conveyed by each of the respective cell types.

Growth factors such as fibroblast growth factor (FGF) and transforming growth factor (TGF)- β are stored in the bone extracellular matrix and when secreted stimulate the local release of bone progenitor cells. Thereafter, factors such as bone morphogenetic proteins (BMPs) and

parathyroid hormone (PTH) influence the development to these progenitors into osteoblasts, the bone-forming cells, whose final differentiation and function are regulated by the interaction of the cell with bone matrix proteins.

5 During ageing an individual is subject to a gradual loss in bone mass, a phenomenon termed uncoupling, which is deemed to result from the activity of osteoclasts exceeding that of osteoblasts. In cases where this uncoupling persists for a longer period of time, more and more of the bone's material gets destroyed/resorbed and a condition termed osteoporosis results.

10 Apart from the age-dependent phenomenon, bone loss may also be brought about by calcium or hormonal deficiency or by conditions which result in a variety of different diseases such as osteoporosis, hypercalcemia, Paget's disease of bone, bone loss due to osteoarthritis or rheumatoid arthritis or osteomyelitis, and the like. The reduced bone density generally leads to a decreased mechanical strength and increased likelihood of fractures.

15 Current approaches for the treatment of osteoporosis and/or related bone disorders include the use of calcium administered to the individual in need thereof. Recently, agents involved in the stimulation and/or inhibition of bone cells, such as hormones, calcitonin, insulin-like growth factor or osteoprotegerin (OPG) have also been envisaged to be usable in treating the above
20 disease conditions. Said agents are generally prepared by recombinant means and have to be formulated/prepared in a galenic form such that the respective substance may reach the target, the bone, in an active form.

The WO 00/24771 discloses nucleic acids encoding osteoprotegerin like proteins and their use in
25 e.g. the treatment of osteoporosis. The polypeptide is synthesized by recombinant means and then formulated so as to be compatible with the intended route of administration. As such routes intravenous, intradermal, subcutaneous, oral (e.g. inhalation), transdermal (topical), transmucosal and rectal administration are proposed.

30 In general it is quite time-consuming and cumbersome to find a suitable galenic form for a given substance, since the ingredients utilised for this purpose must be compatible with the active substance and must also provide sufficient protection against the different conditions in the body.

However, since agents stimulating bone growth are synthesised locally - in/at the bone tissue - it is difficult to administer such a substance. Normally, capsules have to be devised, which assist in passing the substance through the gastro-intestinal tract without getting destroyed by the adverse environmental conditions prevailing therein. However, this route of administration also has some drawbacks since the substance has to pass the liver and be transported in body fluids before it reaches the bone. Furthermore, it often leads to a reduced amount of active biological material reaching the target tissue.

Consequently, a problem of the present invention is to provide a means of administering an active substance to an individual, whereby the substance acts in a specific target tissue in the individual.

Accordingly, the above problem has been solved by providing osteoprotegerin obtainable from milk.

In the figures,

Fig. 1 shows the concentration of osteoprotegerin in human breast milk during various stages of lactation;

Fig. 2 shows a Western blot analysis of human milk fractions under reducing conditions using 10% SDS-gel. Bands for OPG were revealed using the biotinylated anti-OPG polyclonal antibody, BAF805 from R&D Systems and streptavidin-alkaline phosphatase (SAPP);

Fig. 3 shows the restriction map of the plasmid which was integrated into the genomic DNA of *Yarrowia* transformants;

Fig. 4 shows a RT-PCR analysis of human breast milk cells and human mammary gland epithelial cells, MCF-7; Lanes 1 and 2 : β -actin (expected size band: 460 bp); Lanes 3 and 4 : OPG (expected size band: 603 bp); 1. Human breast milk cells; 2. MCF-7; 3. Human breast milk cells; 4. MCF-7;

Fig. 5 shows the results of an experiment, wherein the OPG of the present invention inhibits TRAIL-induced apoptosis of Jurkat cells.

5 Osteoprotegerin (OPG), also known as osteoclastogenesis inhibitory factor (OCIF) and TNF-receptor-like molecule 1 (TR1), is a recently described member of the tumor necrosis factor family of receptors (TNFR). It inhibits osteoclast development both in vitro and in vivo and increases bone density (osteopetrosis). In normal mouse embryos, OPG has been localized within cartilage rudiments of developing bones, as well as in the small intestine.

10 However, unlike other members of the TNF receptor family, OPG does not possess a transmembrane domain. Moreover, it could be shown that OPG is also a receptor for the cytotoxic ligand TRAIL (TNF-related apoptosis-inducing ligand) and is identical to follicular dendritic cell-derived receptor-1. As such, it is presumed to regulate cell death, as well as play an important role in the formation of lymphoid tissues and the regulation of immune responses. Indeed,
15 animals lacking OPG have been shown to exhibit underdeveloped lymphoid tissues.

In the studies leading to the present invention it has now surprisingly been found that in addition to its presence in e.g. the bone tissues, osteoprotegerin may also be found in human breast milk. In consequence, during breast feeding the mother is obviously supplying the newborn with said
20 bioactive substance in a form, capable of surviving in the gastro-intestinal tract. From this it follows that the OPG produced by mammary gland cells obviously differs from OPG isolated from other sources as regards its stability and/or resistance to degradation.

Without wishing to be bound by any theory it is presently believed that the specific glycosylation
25 pattern conveyed to the protein in mammary gland cells renders the polypeptide more stable vis-à-vis the acidic gastric fluid and/or the basic environment encountered in the intestine, so that upon intestinal absorption and transport to the bone tissue, the active domain remains intact and is capable of exerting its biological activity.

30 The OPG of the present invention, i.e. in a form obtainable from milk source, has a polypeptide sequence as identified by SEQ ID. No. 1 and exhibits sizes of about 80, 130 and 200 kDa, respectively, which differs from that obtained by recombinant means (55 kDa).

The OPG of the present invention may be included in an ingestible preparation, which may be a food material, such as e.g. milk, yogurt, curd, cheese, fermented milks, milk-based fermented products, ice-creams, fermented cereal-based products, milk-based powders, infant formulae and also pet food. Likewise, the OPG of the present invention may also be included in an enteral or pharmaceutical composition e.g. selected from the group consisting of solutions, dried oral supplement, liquid oral supplement, dry tube feeding or liquid tube-feeding.

In fact, since the OPG according to the present invention is stable, there is no need to bring the active compound into a specific galenic form so as to protect it from the differing and potentially detrimental conditions prevailing in the gastro-intestinal tract and body fluids.

According to another aspect the present invention also provides for the use of osteoprotegerin from milk for preparing an ingestible preparation, such as a food material or an enteral composition, or a pharmaceutical composition.

The osteoprotegerin of the present invention and the ingestible preparation as detailed above may be used for the treatment and/or prophylaxis of disorders of bone remodeling.

The most common bone disorder is osteopenia, a condition relating in general to any decrease in bone mass to below normal levels. Such a condition may arise from a decrease in the rate of bone synthesis or an increase in the rate of bone destruction or both. The most common form of osteopenia is primary osteoporosis, also referred to as postmenopausal and senile osteoporosis. This form of osteoporosis is a consequence of an universal loss of bone with age and is usually a result of increase in bone resorption with a normal rate of bone formation. Yet other forms of osteoporosis include endocrine osteoporosis (hyperthyroidism, hyperparathyroidism, Cushing's syndrome, and acromegaly), hereditary and congenital forms of osteoporosis (osteogenesis imperfecta, homocystinuria, Menkes' syndrome, and Riley-Day syndrome) and osteoporosis due to immobilization of extremities.

Quite recently, it has been acknowledged that osteoporosis in human populations has also been associated with a higher incidence of arterial calcification, a component of many atherosclerotic

lesions.

Consequently, a food product as illustrated above may well be utilised for preventing the onset of or alleviating symptoms and/or structural changes in the bones associated with osteopenia or osteoporosis, respectively. It will be appreciated that the active substance will be included in the food material in an amount sufficient to effect a desired biological response. Since OPG has been found to be itself a constituent of mother's milk, milk-based products are inherently well suited for delivering the substance to an individual.

On the other hand, for treating severe cases of osteopenia or osteoporosis, respectively, the preferred regimen may be a pharmaceutical composition, which contains the osteoprotegerin according to the present invention in higher amounts, that is in amounts sufficient to stop or even revert the disease process. Such compositions may contain the OPG of the present invention as the only active substance. This has the advantage that no major formulation of the substance has to be envisaged. It is, therefore, well within the present invention to simply press a tablet consisting of "OPG-powder" optionally supplemented with carriers or flavouring agents. However, in the case that the OPG of the present invention shall be formulated together with other active substances, the nature and liability to degradation of these additional substances in the gastrointestinal tract shall be considered. The OPG of the present invention formulated in dosage units, will enable the attending physician to more carefully control the daily or weekly dose of the active compound.

The osteoprotegerin of the present invention may also be utilised for preventing the onset of and/or treating Paget's disease of bone, osteomyelitis, infectious lesions in bone which lead to bone loss, hypercalcemia, osteonecrosis, bone loss due to osteoarthritis or rheumatoid arthritis, periodontal bone loss and/or osteolytic metastasis.

OPG has also been found to be a receptor for the tumor necrosis factor-related ligand (TRAIL) which induces apoptosis upon binding to its death domain-containing receptors. It is presumed to regulate cell death, as well as play an important role in the formation of lymphoid tissues and the regulation of immune responses. Furthermore, OPG is a decoy receptor for RANKL (ligand for the receptor activator of NF- κ B) which has been reported as a product of activated T cells.

Ligation of the receptor for RANKL on mature dendritic cells, enhances dendritic cell survival. Furthermore, the engagement of RANKL with its receptor enhances T-cell growth and dendritic cell function.

5 Accordingly, the present invention provides for the use of osteoprotegerin obtainable from human and/or bovine milk for the manufacture of an ingestible preparation, such as e.g. a dietary composition or an enteral composition, or for the manufacture of a medicament, respectively, for contributing to the normal development of immune tissues, for contributing to normal immune function and even for preventing and/or treating disorders of the immune system.

10 Disorders of the immune system contemplated in the present invention comprise allergy, autoimmunity, sepsis, cancer, inflammatory bowel diseases, systemic autoimmune conditions, cardiovascular disease and immunopathological conditions of the skin, the oral cavity, the gastrointestinal, urogenital or respiratory tracts.

15 In addition the osteoprotegerin of the present invention may likewise be applied for the regulation of cell proliferation and apoptosis, for the promotion of oral tolerance, the modulation of infectious processes and bacterial colonization of the neonate. Especially for neonates the above mentioned disorders may by and large be associated with prematurity and/or low birth weight, so that in these cases the osteoprotegerin of the present invention may simply be administered to the baby by means of baby food.

25 It will be appreciated that an individual at any age may be the individual to be treated, though babies and elderly are the main subjects to be considered due to their inherent requirement of exogenous osteoprotegerin. In particular individuals, such as newborns, require osteoprotegerin for the development of bone material and/or the immune system, so that in these cases the compound and/or the food material and/or the pharmaceutical composition of the present invention may be advantageously be administered.

30 However, it will be appreciated that the present invention may also be applied to adults, in order to prevent the onset of any of the above disorders. It will also be appreciated that apart from humans the individuals to be treated may also be animals, such as pets, in that the OPG of the

present invention is included in pet food.

The OPG of the present invention may be obtained from a milk source, derived from a mammal, in particular from human or bovine milk or colostrum. Human milk OPG has an amino acid sequence of 380 aa and exhibits a molecular weight of approximately 80, 130 and 200 kda when compared to protein markers which were used as molecular weight standards (BioRad). It exhibits 4 sites for N-glycosylation and may be present in a monomeric form and a dimeric form by forming a S-S bond via Cys³⁷⁹.

The OPG of the present invention may be isolated from milk sources, such as human or bovine milk. However, it will be appreciated that the present OPG may be prepared by recombinant means in appropriate cells yielding a glycosylation pattern as found in the "milk-OPG". Preferred cells for expression are those of the mammary gland, since these cells may be expected to yield an identical or essentially identical glycosylation pattern.

Suitable cells for expressing the present OPG may be obtained by immortalization with appropriate means, such as the SV40 vector or the telomerase gene, and transformation with an expression vector containing a nucleotide sequence encoding the OPG polypeptide. The polypeptide of interest may be obtained by isolating it from the supernatant, in the event that the polypeptide is secreted, or by collecting the cells and isolating the polypeptide from the cells themselves. In the event of a continuous production, isolation from the supernatant will be preferred.

The following examples illustrate the invention without limiting it thereto.

Examples

Human milk and human serum samples

Human breast milk samples (10-60 ml) from healthy mothers were collected up to 17 days post-partum under sterile conditions by breast pump expression or occasionally by manual expression. The milk was expressed into sterile 50 ml centrifugation tubes and processed within 2 hrs of collection. Following centrifugation (200 x g, 10 min), the cellular pellet was immediately

removed and treated for RNA extraction. The remainder of the milk was frozen at -20°C . Human serum samples were obtained from healthy donors and kept at -20°C .

Fractionation of human breast milk

Cream was extracted from whole milk by high speed centrifugation. The top cream layer was removed, washed in water and the cream washings were frozen at -20°C until required. The separation of whey and casein was achieved by rennet enzyme treatment or chemical acidification (with HCl) of skimmed milk inducing casein clotting. Centrifugation of the treated milk then separates sweet whey from the non-soluble rennet casein and acid whey from acid casein respectively. Finally, soluble milk proteins (ultracentrifuged whey) and non soluble, micellar casein were prepared using ultracentrifugation. All casein and whey fractions were frozen at -20°C until required.

Human mammary cell line

MCF-7 (American Type Culture Center (ATCC), Manassas, VA., HTB-22), a human mammary cell line derived from the pleural effusion of a breast carcinoma, retains several characteristics of differentiated mammary epithelium. The cells were cultured in DMEM (Amimed Bioconcept, Allschwill, Switzerland) supplemented with 10% foetal calf serum (FCS, Amimed Bioconcept) and maintained at 37°C in a humidified atmosphere containing 5% CO_2 . The culture media was changed 2 to 3 times per week. Upon reaching confluency, cells were detached using trypsin/EDTA (GibcoBRL) at 37°C . The cells were then prepared for RNA extraction.

Western blot analysis

Milk samples were diluted 1/25 with Laemmli reducing sample buffer and boiled for 5 min. The proteins were separated by 10% SDS-PAGE and transferred to nitrocellulose membranes (BioRad). The blots were probed with a biotinylated polyclonal anti-human OPG (BAF805 at $0.2\text{ }\mu\text{g/ml}$; R&D systems) and streptavidin-alkaline phosphatase (Pierce). Immunoreactivity was visualised with alkaline phosphatase substrate BCIP/NBT (Zymed Laboratories). Prestained

protein markers were used as molecular weight standards (BioRad). Recombinant human OPG (R&D systems) was load at 25ng/lane served as a positive control.

Expression of OPG by human breast milk cells and human mammary gland epithelial cells

Reverse transcription followed by PCR was used to amplify OPG transcripts in the total human breast milk cell population from a single mother at 18 days postpartum and in the human mammary gland epithelial cell line, MCF-7. Total RNA was extracted from the cells using the Trizol method (Gibco-BRL). Briefly, the Trizol (1 ml for $5-10 \times 10^6$ cells) was added to the cell pellet, pipetted up and down several times and transferred into an Eppendorf tube. Chloroform was added (0.2 ml for 1 ml Trizol), and the tubes were incubated for 5 min before centrifugation at $12,000 \times g$ for 15 min, 4°C . RNA was precipitated with an equal volume of isopropanol and centrifuged at $12,000 \times g$ for 10 min. Pellets were washed with 70% ethanol and then resuspended in sterile, deionized water. RNA was stored at -20°C until required.

RNA samples were treated with RNase-free DNase I to eliminate contamination by genomic DNA. RNA was quantified by absorbance at 260 nm and 280 nm of an appropriate dilution (100–200 fold) in a spectrophotometer. The concentration of RNA ($\mu\text{g/ml}$) was calculated as follow: Absorbance at $A_{260} \times \text{dilution factor} \times 40 \text{ mg/ml}$. A total RNA sample that is essentially free of proteins should have an A_{260}/A_{280} ratio of 1.8 – 2.2.

RNA was reverse-transcribed with Moloney murine leukemia virus reverse transcriptase (Perkin-Elmer). RNA samples (0.5 μg of total RNA), 0.5 unit of RNase inhibitor, 1 mM of each dNTP, 0.5 nmol/ml of specific 3' primer, 5 mM MgCl_2 and 1.25 units of reverse transcriptase were incubated in a total volume of 10 μl of reaction mixture containing the enzyme buffer supplied by the manufacturer. The reaction mixture was incubated for 30 min at 42°C , and then heated for 5 min at 95°C . The reverse-transcribed products were then amplified with Gold DNA polymerase (Perkin Elmer) on a thermocycler (Biolabo, Scientific Instruments, Chatel St Denis, Switzerland). The polymerase chain reaction (PCR) was performed in a total volume of 50 μl using 10 μl of the reverse-transcribed products in PCR buffer, 2 mM MgCl_2 , 5 μM of each dNTP, 0.2 nmol/ml of both OPG-specific antisense

ACTAGTTATAAGCAGCTTATTTTACTG,

and sense

GGAGGCATTCTTCAGGTTTGCTG

5 primers and 1.25 units of DNA polymerase. After an initial denaturation step of 10 min at 95°C, samples were amplified by 35 cycles of denaturation at 94°C for 45 sec, annealing at 60°C for 1 min, and extension at 72°C of 1 min 30 sec, followed by a 7-min extension step at 72°C. All samples were subjected to RT-PCR with β -actin as a positive control. Samples of RT-PCR products were loaded onto a 1.2 % agarose gels (containing ethidium bromide) in 1 x TAE buffer
10 and separated by electrophoresis at 150 V for 1 hr. RT-PCR products were visualised under UV light. The correct size of the bands was determined by comparison with DNA size markers (Boehringer Mannheim).

15 ELISA for Human OPG-(sandwich enzyme immunoassay)

The concentration of OPG present in breast milk and different milk fractions was measured by ELISA. To this end, monoclonal antibodies against OPG (MAB805, 1 μ g/ml; R&D Systems, UK) were coated onto 96-well plates (Nunc) by overnight incubation at 4°C. Plates were then washed twice with 0.05% Tween-20 in PBS. Non-specific binding was blocked by incubating
20 the plates with 2% bovine serum albumin (BSA) in PBS for additional 2 hrs at room temperature. Samples or standard concentrations of recombinant OPG (0.119 to 121.5 ng/ml; R&D Systems) were incubated in PBS-BSA for 3 hrs at room temperature. Plates were then washed four times with PBS-Tween before addition of biotin-labelled anti-human OPG polyclonal antibody (BAF805, 0.5 μ g/ml; R&D Systems) for another hour at room temperature. After an additional
25 four washes, streptavidin-peroxidase (SAAP, 0.5 μ g/ml. Kirkegaard % Perry KPL) was added for 1 hr at room temperature. Plates were then washed four times, and the substrate TMB peroxidase (KPL) was added. Plates were covered and incubated in the dark for five minutes. The enzymatic reaction was terminated by the addition of 1N HCl. Absorbance was read at 450 nm in an ELISA reader (Dynex Technologies). The detection limit was approximately 30 pg/ml.

30

Biological activity of human milk OPG

OPG is a receptor for the tumour necrosis factor-related ligand (TRAIL) which induces apoptosis

upon binding to its death domain-containing receptors, DR4 and DR5. A bioassay was developed in which human breast milk OPG could be tested for its ability to block the TRAIL-induced apoptosis of these cells.

5 In this respect Jurkat cells, clone E6-1 (ATCC), were maintained in culture in RPMI 1640 as modified by the supplier ATCC and containing 10% FCS (37°C and 5% CO₂). Cells were seeded at a density of 5×10^4 cells/well in 96-well plates (Nunc). To each well various concentrations of soluble recombinant human TRAIL (0 to 20 ng/ml) were added in the presence of 2 µg/ml of enhancer protein, an antibody which reacts with soluble recombinant human TRAIL and thereby
10 increases its activity (Alexis, Läufelfingen, CH). Some wells also contained 50 ng/ml recombinant human OPG (R&D Systems), human breast milk samples (HM; 1/80 final dilution; collected at 1d or 9d postpartum) and/or 20 µg/ml anti-OPG monoclonal antibody (MAB805, R&D Systems). Plates were incubated at 37°C for 16 hrs. Cell viability was measured by adding ³H-thymidine (1 µCi/well) during the last 6 hrs of culture.

15

In the medium control, a TRAIL-induced inhibition of cell proliferation was evident at concentrations greater than 5ng/ml. However, HM samples prevented this inhibition. This effect was obviously due to the presence of OPG, since the at-OPG monoclonal antibody reversed the effect.

20 The results are shown in figure 5.

Western blot analysis

OPG is synthesised as a 55kDa monomer within cells but is converted to a disulphide-linked
25 dimer of approximately 110kDa when secreted extracellularly. In milk bands were detected at approximately 80, 130 and 200 kDa.

Concentrations of OPG in human breast milk

30

Levels of OPG in the breast milk samples of 10 lactating mothers at different times during the first 17 days of lactation were examined by ELISA. Concentrations increased to maximum values during the first 1-3 days of lactation and then decreased thereafter. Concentrations in milk

ranged from 50 ng/ml to almost 2 µg/ml (Fig. 1).

Cellular source of milk OPG

RT-PCR analysis revealed that the OPG of the present invention may be found in human breast milk cells and mammary gland epithelial cells. Constitutive expression of mRNA for OPG was evident in both types of untreated cells (Figure 4).

Cloning of human milk OPG in yeast

Cells were isolated from human breast milk (18 days post-partum) by centrifugation (200 x g, 10 min). From the cell pellet, total RNA was extracted using TRIzol® (Life Technologies, Basel, Switzerland), DNaseI treated and further purified on RNeasy spin columns (Qiagen, Basel) as recommended by the manufacturers. A PCR product encoding the mature form of OPG was amplified from this total RNA using the Titan™One tube RT-PCR system following the protocol supplied by the manufacturer (Roche Diagnostics, Rotkreuz).

With the OPG specific antisense primer

CCGGCCTCTTCGGCCGCCAAGCGAGAAACGTTTCCTCCAAAGTACC,

and the sense primer

ACTAGTTATAAGCAGCTTATTTTACTG,

a 1174 bp PCR fragment was amplified from this cDNA. The PCR product was *SfiI-SpeI* digested, gel purified and the resulting 1156 bp fragment ligated to *SfiI-XbaI* digested and SAP-treated pINA1267, creating pNFF270. This plasmid pNFF270 was then introduced into the yeast *Yarrowia lipolytica* by transformation. Figure 3 depicts the restriction map of the plasmid which was integrated into the genomic DNA of *Yarrowia* transformants and SEQ ID. No. 1 the protein encoded by this OPG plasmid.

The sequence of a pGEM-T OPG clone is shown in Figure 6. The mature OPG is in black and translated. In the published OPG/OCIF sequence, amino acid residue 242 of the mature OPG is an Ala-residue (A), whereas all pGEM-T OPG clones analysed, encoded an Asp-residue (D) at

this position. The *SfiI-SpeI* OPG fragment of this clone was transferred to *SfiI-XbaI* digested pINA1267. The resulting plasmid had the restriction map depicted in Figure 3. A single copy of this plasmid was integrated into the genomic DNA of *Yarrowia* transformants. The protein encoded by this plasmid is shown in Figure 4. The mature OPG is indicated in bold print. The plasmid pNFF270 was introduced into *Yarrowia lipolytica* by transformation. The resulting transformants secreted a protein, cross-reacting with OPG-specific antibodies into the culture medium while *Y. lipolytica* transformants carrying the empty expression vector did not secrete such a protein.

Claims

1. Osteoprotegerin, obtainable from human or bovine milk or colostrum.
2. The osteoprotegerin according to claim 1, wherein the osteoprotegerin has a glycosylation pattern giving rise to a polypeptide having a molecular weight of approximately 80, 130 and 200 kDa.
3. A food material containing an osteoprotegerin according to any of the claims 1 or 2.
4. The food material which is selected from the group consisting of milk, yogurt, curd, cheese, fermented milks, milk-based fermented products, ice-creams, fermented cereal-based products, milk-based powders, infant formulae and pet food.
5. An enteral composition or a pharmaceutical composition containing an osteoprotegerin according to any of the claims 1 or 2.
6. The enteral or pharmaceutical composition according to claim 5, which is selected from the group consisting of solutions, dried oral supplement, liquid oral supplement, dry tube-feeding or liquid tube-feeding.
7. Use of osteoprotegerin according to claim 1 or 2 for the manufacture of an ingestable preparation.
8. The use according to claim 7, wherein the ingestable preparation is a food material according to claim 3 or 4 or a composition according to claim 5 or 6.
9. Use of osteoprotegerin according to claim 1 or 2 for preparing a material or a composition according to any of the claims 3 to 6 for the treatment of disorders associated with bone remodeling.

10. The use according to claim 9, wherein the disorder is osteoporosis, Paget's disease of bone, Osteomyelitis, infectious lesions in bone leading to bone loss, hypercalcemia, osteopenia, osteonecrosis, bone loss due to osteoarthritis or rheumatoid arthritis, periodontal bone loss and/or osteolytic metastasis.
- 5 11. Use of osteoprotegerin according to claim 1 or 2 for preparing a material or a composition according to any of the claims 3 to 6 for the treatment of and/or prophylaxis of immune disorders.
- 10 12. The use according to claim 11, wherein the disorder is allergy, autoimmunity, inflammatory bowel diseases, systemic autoimmune conditions, dysregulation of cell proliferation and apoptosis and immunopathological conditions of the skin, the oral cavity, the gastrointestinal, urogenital or respiratory tracts.
- 15 13. The use according to any of the claims 9 to 12, wherein the disorders are associated with prematurity and/or low birth weight.
- 20 14. Use of osteoprotegerin according to claim 1 or 2 for preparing a material or a composition according to any of the claims 3 to 6 for the development of bone material and/or the immune system.

Summary

- 5 The present invention pertains to osteoprotegerin obtainable from milk sources, in particular human and bovine milk. The present invention also relates to the use thereof for preparing an ingestible preparation and/or a pharmaceutical composition, in particular to the use of such a preparation/composition for preventing or treating disorders associated with bone metabolism and immune function.

SEQUENCE LISTING

<110> Société des Produits Nestlé, S. A.

<120> Osteoprotegerin in milk and its use in regulating bone metabolism

<130> 80280

<140>

<141>

<160> 7

<170> PatentIn Ver. 2.1

<210> 1

<211> 380

<212> PRT

<213> Homo sapiens sapiens

<400> 1

Glu	Thr	Phe	Pro	Pro	Lys	Tyr	Leu	His	Tyr	Asp	Glu	Glu	Thr	Ser	His
1				5					10					15	

Gln	Leu	Leu	Cys	Asp	Lys	Cys	Pro	Pro	Gly	Thr	Tyr	Leu	Lys	Gln	His
			20					25					30		

Cys	Thr	Ala	Lys	Trp	Lys	Thr	Val	Cys	Ala	Pro	Cys	Pro	Asp	His	Tyr
		35					40					45			

Tyr	Thr	Asp	Ser	Trp	His	Thr	Ser	Asp	Glu	Cys	Leu	Tyr	Cys	Ser	Pro
	50					55					60				

Val	Cys	Lys	Glu	Leu	Gln	Tyr	Val	Lys	Gln	Glu	Cys	Asn	Arg	Thr	His
65					70					75					80

Asn	Arg	Val	Cys	Glu	Cys	Lys	Glu	Gly	Arg	Tyr	Leu	Glu	Ile	Glu	Phe
			85						90					95	

Cys	Leu	Lys	His	Arg	Ser	Cys	Pro	Pro	Gly	Phe	Gly	Val	Val	Gln	Ala
			100						105				110		

Gly	Thr	Pro	Glu	Arg	Asn	Thr	Val	Cys	Lys	Arg	Cys	Pro	Asp	Gly	Phe
		115					120					125			

Phe	Ser	Asn	Glu	Thr	Ser	Ser	Lys	Ala	Pro	Cys	Arg	Lys	His	Thr	Asn
		130					135					140			

EPO-Madrid
03. April 2001

Cys Ser Val Phe Gly Leu Leu Leu Thr Gln Lys Gly Asn Ala Thr His
 145 150 155 160

Asp Asn Ile Cys Ser Gly Asn Ser Glu Ser Thr Gln Lys Cys Gly Ile
 165 170 175

Asp Val Thr Leu Cys Glu Glu Ala Phe Phe Arg Phe Ala Val Pro Thr
 180 185 190

Lys Phe Thr Pro Asn Trp Leu Ser Val Leu Val Asp Asn Leu Pro Gly
 195 200 205

Thr Lys Val Asn Ala Glu Ser Val Glu Arg Ile Lys Arg Gln His Ser
 210 215 220

Ser Gln Glu Gln Thr Phe Gln Leu Leu Lys Leu Trp Lys His Gln Asn
 225 230 235 240

Lys Asp Gln Asp Ile Val Lys Lys Ile Ile Gln Asp Ile Asp Leu Cys
 245 250 255

Glu Asn Ser Val Gln Arg His Ile Gly His Ala Asn Leu Thr Phe Glu
 260 265 270

Gln Leu Arg Ser Leu Met Glu Ser Leu Pro Gly Lys Lys Val Gly Ala
 275 280 285

Glu Asp Ile Glu Lys Thr Ile Lys Ala Cys Lys Pro Ser Asp Gln Ile
 290 295 300

Leu Lys Leu Leu Ser Leu Trp Arg Ile Lys Asn Gly Asp Gln Asp Thr
 305 310 315 320

Leu Lys Gly Leu Met His Ala Leu Lys His Ser Lys Thr Tyr His Phe
 325 330 335

Pro Lys Thr Val Thr Gln Ser Leu Lys Lys Thr Ile Arg Phe Leu His
 340 345 350

Ser Phe Thr Met Tyr Lys Leu Tyr Gln Lys Leu Phe Leu Glu Met Ile
 355 360 365

Gly Asn Gln Val Gln Ser Val Lys Ile Ser Cys Leu
 370 375 380

<210> 2

<211> 1182

<212> DNA

<213> Homo sapiens sapiens

<400> 2

```
tccggcctct tccggccgcca agcgagaaac gtttcctcca aagtaccttc attatgacga 60
agaaacctct catcagctgt tgtgtgacaa atgtcctcct ggtacctacc taaaacaaca 120
ctgtacagca aagtggaaga ccgtgtgcmc cccttgccct gaccactact acacagacag 180
ctggcacacc agtgacgagt gtctatactg cagccccgtg tgcaaggagc tgcagtacgt 240
caagcaggag tgcaatcgca cccacaaccg cgtgtgcmga tgcaaggagc ggcgctacct 300
tgagatagag ttctgcttga aacataggag ctgccctcct ggatttggag tgggtgcaagc 360
tggaacccca gagcgaaata cagtttgcaa aagatgtcca gatgggttct tctcaaata 420
gacgtcatct aaagcaccct gtagaaaaca cacaatttgc agtgtctttg gtctcctgct 480
aactcagaaa ggaaatgcaa cacacgacaa catatgttcc ggaaacagtg aatcaactca 540
aaaatgtgga atagatgtta cctgtgtgga ggaggcattc ttcagggttg ctgttcctac 600
aaagtttacg cctaactggc ttagtgtctt ggtagacaat ttgcctggca ccaaagtaaa 660
cgcagagagt gtagagagga taaaacggca acacagctca caagaacaga ctttccagct 720
gctgaagtta tggaacatc aaaacaaaga ccaagatata gtcaagaaga tcatccaaga 780
tattgacctc tgtgaaaaca gcgtgcagcg gcacattgga catgctaacc tcaccttcca 840
gcagcttcgt agcttgatgg aaagcttacc gggaaagaaa gtgggagcag aagacattga 900
aaaaacaata aaggcatgca aaccctagtga ccagatcctg aagctgctca gtttgtggcg 960
aataaaaaat ggcgaccaag acaccttgaa ggcctaatag cagcactaa agcactcaaa 1020
gacgtaccac tttcccaaaa ctgtcactca gagtctaaag aagaccatca ggttccttca 1080
cagcttcaca atgtacaaat tgtatcagaa gttattttta gaaatgatag gtaaccaggt 1140
ccaatcagta aaaataagct gcttataact agtatcacta gt 1182
```

<210> 3

<211> 537

<212> PRT

<213> Homo sapiens sapiens

<400> 3

```
Met Lys Leu Ala Thr Ala Phe Thr Ile Leu Thr Ala Val Leu Ala Ala
 1             5             10             15

Pro Leu Ala Ala Pro Ala Pro Ala Pro Asp Ala Ala Pro Ala Ala Val
          20             25             30

Pro Glu Gly Pro Ala Ala Ala Ala Tyr Ser Ser Ile Leu Ser Val Val
          35             40             45

Ala Lys Gln Ser Lys Lys Phe Lys His His Lys Arg Asp Leu Asp Glu
          50             55             60

Lys Asp Gln Phe Ile Val Val Phe Asp Ser Ser Ala Thr Val Asp Gln
65             70             75             80
```

Ile Ala Ser Glu Ile Gln Lys Leu Asp Ser Leu Val Asp Glu Asp Ser
 85 90 95

Ser Asn Gly Ile Thr Ser Ala Leu Asp Leu Pro Val Tyr Thr Asp Gly
 100 105 110

Ser Gly Phe Leu Gly Phe Val Gly Lys Phe Asn Ser Thr Ile Val Asp
 115 120 125

Lys Leu Lys Glu Ser Ser Val Leu Thr Val Glu Pro Asp Thr Ile Val
 130 135 140

Ser Leu Pro Glu Ile Pro Ala Ser Ser Ala Ala Lys Arg Glu Thr Phe
 145 150 155 160

Pro Pro Lys Tyr Leu His Tyr Asp Glu Glu Thr Ser His Gln Leu Leu
 165 170 175

Cys Asp Lys Cys Pro Pro Gly Thr Tyr Leu Lys Gln His Cys Thr Ala
 180 185 190

Lys Trp Lys Thr Val Cys Ala Pro Cys Pro Asp His Tyr Tyr Thr Asp
 195 200 205

Ser Trp His Thr Ser Asp Glu Cys Leu Tyr Cys Ser Pro Val Cys Lys
 210 215 220

Glu Leu Gln Tyr Val Lys Gln Glu Cys Asn Arg Thr His Asn Arg Val
 225 230 235 240

Cys Glu Cys Lys Glu Gly Arg Tyr Leu Glu Ile Glu Phe Cys Leu Lys
 245 250 255

His Arg Ser Cys Pro Pro Gly Phe Gly Val Val Gln Ala Gly Thr Pro
 260 265 270

Glu Arg Asn Thr Val Cys Lys Arg Cys Pro Asp Gly Phe Phe Ser Asn
 275 280 285

Glu Thr Ser Ser Lys Ala Pro Cys Arg Lys His Thr Asn Cys Ser Val
 290 295 300

Phe Gly Leu Leu Leu Thr Gln Lys Gly Asn Ala Thr His Asp Asn Ile
 305 310 315 320

Cys Ser Gly Asn Ser Glu Ser Thr Gln Lys Cys Gly Ile Asp Val Thr
 325 330 335

Leu Cys Glu Glu Ala Phe Phe Arg Phe Ala Val Pro Thr Lys Phe Thr
 340 345 350

Pro Asn Trp Leu Ser Val Leu Val Asp Asn Leu Pro Gly Thr Lys Val
 355 360 365

Asn Ala Glu Ser Val Glu Arg Ile Lys Arg Gln His Ser Ser Gln Glu
 370 375 380

Gln Thr Phe Gln Leu Leu Lys Leu Trp Lys His Gln Asn Lys Ala Gln
 385 390 395 400

Asp Ile Val Lys Lys Ile Ile Gln Asp Ile Asp Leu Cys Glu Asn Ser
 405 410 415

Val Gln Arg His Ile Gly His Ala Asn Leu Thr Phe Glu Gln Leu Arg
 420 425 430

Ser Leu Met Glu Ser Leu Pro Gly Lys Lys Val Gly Ala Glu Asp Ile
 435 440 445

Glu Lys Thr Ile Lys Ala Cys Lys Pro Ser Asp Gln Ile Leu Lys Leu
 450 455 460

Leu Ser Leu Trp Arg Ile Lys Asn Gly Asp Gln Asp Thr Leu Lys Gly
 465 470 475 480

Leu Met His Ala Leu Lys His Ser Lys Thr Tyr His Phe Pro Lys Thr
 485 490 495

Val Thr Gln Ser Leu Lys Lys Thr Ile Arg Phe Leu His Ser Phe Thr
 500 505 510

Met Tyr Lys Leu Tyr Gln Lys Leu Phe Leu Glu Met Ile Gly Asn Gln
 515 520 525

Val Gln Ser Val Lys Ile Ser Cys Leu
 530 535

<210> 4

<211> 28

<212> DNA

<213> Homo sapiens sapiens

<400> 4

actagttata agcagcttat ttttactg

28

<210> 5
<211> 23
<212> DNA
<213> Homo sapiens sapiens

<400> 5
ggaggcattc ttcaggtttg ctg 23

<210> 6
<211> 46
<212> DNA
<213> Homo sapiens sapiens

<400> 6
ccggcctctt cggccgccaa gcgagaaacg tttcctccaa agtacc 46

<210> 7
<211> 28
<212> DNA
<213> Homo sapiens sapiens

<400> 7
actagttata agcagcttat ttttactg 28